Study details
Enrolling now
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Milton S. Hershey Medical Center
NCT IDNCT04414514ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
24
Study length
about 5.3 years
Ages
12+
Locations
1 site in PA
About this study
This trial is testing a new treatment called ruxolitinib 1.5% cream applied directly to the skin for hidradenitis suppurativa (HS). The goal is to see if this topical treatment can reduce HS symptoms and inflammation, as well as analyze skin samples from participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ruxolitinib 1.5% Cream
PhasePhase 2
DrugRuxolitinib 1.5% Cream
Routetopical
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
topical